Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hikma Pharmaceuticals Share News (HIK)
HIK Share
Price
HIK Share
News
HIK Share
Chat
HIK Share
Trades912
HIK
Live RNS
HIK Share
Charts
HIK Level 2
Console
HIK Live
Share Price
HIK Broker
Ratings
HIK Directors
Deals
HIK Financial
Diary
HIK
Fundamentals
HIK Short
Positions2
HIK
Media
HIK Company
Research
HIK Company
Timeline2
Hikma Pharmaceuticals Information
Share Price Information for Hikma Pharmaceuticals (HIK)
Share Price is delayed by 15 minutes
Get Live Data
1,531.00
1.00 (0.07%)
Bid:
1,531.00
Ask:
1,532.00
Spread:
1.00 (0.065%)
Market Cap:
£3.22b
Last checked at -
Last checked at 
Intraday Hikma Pharmaceuticals Share Chart
Hikma Pharmaceuticals News
27 Sep 2021
LONDON MARKET OPEN: Rolls-Royce rises on US Air Force contract win
LONDON MARKET OPEN: Rolls-Royce rises on US Air Force contract win
27 Sep 2021
TOP NEWS: Hikma buys US injectables firm Custopharm for USD375 million
TOP NEWS: Hikma buys US injectables firm Custopharm for USD375 million
27 Sep 2021
LONDON MARKET PRE-OPEN: Rolls-Royce wins USD2.6 billion B-52 contract
LONDON MARKET PRE-OPEN: Rolls-Royce wins USD2.6 billion B-52 contract
27 Sep 2021
Hikma buys Custopharm for $375m
(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free...
27 Sep 2021
Hikma buys Custopharm for $375m
(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free...
2 Sep 2021
LONDON BROKER RATINGS: JPMorgan downgrades Unilever and Coca-Cola HBC
LONDON BROKER RATINGS: JPMorgan downgrades Unilever and Coca-Cola HBC
27 Aug 2021
Hikma, Bio-Thera enter exclusive agreement for monoclonal antibody
(Sharecast News) - Bio-Thera Solutions and Hikma Pharmaceuticals have entered into a commercialisation and license agreement to commercialise a monocl...
Follow the stocks
